newsfilter
← Latest News
Business Wire·

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

— Multitarget Approach Has Potential to Further Improve Outcomes in This Disease Characterized by Continued Unmet Need — Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) today announced the initiation of PRESERVE, a Phase